Patents Assigned to Xenon Pharmaceuticals Inc.
  • SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
    Publication number: 20120295897
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Application
    Filed: July 25, 2012
    Publication date: November 22, 2012
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Yurevna Zenova, Qi Jia, Jean-Jacques Cadieux, Simon J. Gauthier, Amy Frances Douglas, Tom Hsieh, Nagasree Chakka, Zoran Cikojevic
  • Spiro-oxindole compounds and their use as therapeutic agents
    Patent number: 8263606
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: September 11, 2012
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Zenova, Qi Jia, Jean-Jacques Cadieux, Simon J. Gauthier, Amy Frances Douglas, Tom Hsieh, Nagasree Chakka, Zoran Cikojevic
  • Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
    Patent number: 8252578
    Abstract: Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e. capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g. by recombinant means. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: August 28, 2012
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Yigal P Goldberg, Rajender K Kamboj
  • Heterocyclic inhibitors of stearoyl-CoA desaturase
    Patent number: 8236835
    Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: August 7, 2012
    Assignees: Novartis AG, Xenon Pharmaceuticals Inc.
    Inventors: Natalie Dales, Zaihui Zhang, Rajender Kamboj, Jianmin Fu, Shaoyi Sun, Natalia Pokrovskaia, Serguei Sviridov
  • SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
    Publication number: 20120122909
    Abstract: This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
    Type: Application
    Filed: April 1, 2011
    Publication date: May 17, 2012
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Nagasree Chakka, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Duanjie Hou, Tom Hsieh, Rajender Kamboj, Shifeng Liu, Vandna Ralna, Mehran Seid Bagherzadeh, Jianyu Sun, Shaoyi Sun, Serguei Sviridov
  • Pyridyl derivatives and their use as therapeutic agents
    Patent number: 8153636
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein x, y, W, V, R1, R2, R3, R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10 and R10a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: April 10, 2012
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Melwyn Abreo, Daniel F. Harvey, Heinz W. Gschwend, Wenbao Li, Chi Tu, Rajender Kamboj, Michael D. Winther, Vishnumurthy Kodumuru, Cindy J. Hudson, Mikhail A. Kondratenko, Shifeng Liu, Vandna Raina, Serguei Sviridov, Zaihui Zhang, Mehran Seid Bagherzadeh, Shaoyi Sun
  • Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammal
    Patent number: 8148378
    Abstract: A method of treating an SCD-mediated disease or condition in a mammal, preferably a human, includes administering to a mammal a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein. The SCD-mediated disease or condition may be selected from the group consisting of Type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia, metabolic syndrome, acne, cardiovascular disease, hypertriglyceridemia, inflammation, cancer, and any combination of these.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: April 3, 2012
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Heinz W. Gschwend, Vishnumurthy Kodumuru, Shifeng Liu, Rajender Kamboj
  • SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
    Publication number: 20120035199
    Abstract: This invention is directed to spiroheterocyclic compounds of formula (I): wherein k, j, p, Q, R1, R3a, R3b, R3e, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: August 12, 2010
    Publication date: February 9, 2012
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Rajender Kamboj, Shifeng Liu, Mehran Seid Bagherzadeh, Jianyu Sun, Serguei Sviridov
  • Spiro-oxindole compounds and their uses as therapeutic agents
    Patent number: 8106087
    Abstract: This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: January 31, 2012
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Nagasree Chakka, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Duanjie Hou, Tom Hsieh, Rajender Kamboj, Shifeng Liu, Vandna Raina, Mehran Seid Bagherzadeh, Jianyu Sun, Shaoyi Sun, Serguei Sviridov
  • Spiro-oxindole compounds and their use as therapeutic agents
    Patent number: 8101647
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: January 24, 2012
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Zenova
  • ORGANIC COMPOUNDS
    Publication number: 20120014906
    Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: September 21, 2011
    Publication date: January 19, 2012
    Applicants: XENON PHARMACEUTICALS INC., NOVARTIS AG
    Inventors: Sultan Chowdhury, Natalie Dales, Julia Fonarev, Jianmin Fu, Duanjie Hou, Qi Jia, Vishnumurthy Kodumuru, Natalia Pokrovskaia, Shaoyi Sun, Zaihui Zhang
  • SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE
    Publication number: 20120010135
    Abstract: The present invention provides spiro derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: March 30, 2010
    Publication date: January 12, 2012
    Applicants: XENON PHARMACEUTICALS INC., NOVARTIS AG
    Inventors: Natalie Dales, Julia Fonarev, Jianmin Fu, Zaihui Zhang
  • Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
    Patent number: 8080651
    Abstract: Polynucleotide and polypeptide sequences for HFE2A, as well as mutations associated with juvenile hemochromatosis, and methods of utilizing these for the screening and identification of agents for the treatment of diseases of iron metabolism, including small organic compounds, are disclosed along with methods of treating and/or ameliorating diseases of iron metabolism, especially in human patients are disclosed. Diagnostic compounds, kits and methods using HFE2A are also described.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: December 20, 2011
    Assignee: Xenon Pharmaceuticals Inc.
    Inventor: Yigal P. Goldberg
  • Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
    Patent number: 8071603
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: December 6, 2011
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Zaihui Zhang, Serguei Sviridov, Vandna Raina, Duanjie Hou, Vishnumurthy Kodumuru, Mehran Seid Bagherzadeh
  • SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN
    Publication number: 20110294842
    Abstract: This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R1, R2a, R2b, R2c, R2d and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Application
    Filed: October 12, 2007
    Publication date: December 1, 2011
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Jacques Cadieux, Sultan Chowdhury, Jianmin Fu, Rajender Kamboj, Tom Hsieh, Qi Jia, Shifeng Liu, Jianyu Sun
  • Polynucleotide encoding an ATP binding cassette transporter 1 (ABC1) polypeptide
    Patent number: 8067219
    Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: November 29, 2011
    Assignees: Xenon Pharmaceuticals Inc., University of British Columbia
    Inventors: Michael R. Hayden, Angela R. Brooks-Wilson, Simon N. Pimstone
  • Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
    Patent number: 8063084
    Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: November 22, 2011
    Assignees: Novartis AG, Xenon Pharmaceuticals Inc.
    Inventors: Natalie Dales, Julia Fonarev, Jianmin Fu, Rajender Kamboj, Vishnumurthy Kodumuru, Shifeng Liu, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Zaihui Zhang
  • SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS
    Publication number: 20110269788
    Abstract: This invention is directed to spiro-oxindole compounds of formulas (I), (II), (III), as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Application
    Filed: December 29, 2009
    Publication date: November 3, 2011
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Jacques Cadieux, Mikhail Chafeev, Sultan Chowdhury, Amy Frances Douglas, Jianmin Fu, Jonathan Langille, Shaoyi Sun, Mark Wood
  • Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes
    Patent number: 8049016
    Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: November 1, 2011
    Assignees: Novartis AG, Xenon Pharmaceuticals Inc
    Inventors: Sultan Chowdhury, Natalie Dales, Julia Fonarev, Jianmin Fu, Duanjie Hou, Qi Jia, Vishnumurthy Kodumuru, Natalia Pokrovskaia, Shaoyi Sun, Zaihui Zhang
  • Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents
    Patent number: 8030488
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where G, J, L, M, x, y, W, V, R2, R3, R4, R5, R6, R7, R8, R8a, R9, R9a, R10, R10a, R11 and R11a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: October 4, 2011
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Serguei Sviridov, Vishnumurthy Kodumuru, Shifeng Liu, Melwyn Abreo, Michael D. Winther, Heinz W. Gschwend, Rajender Kamboj, Shaoyi Sun, Mark W. Holladay, Wenbao Li, Chi Tu